| OFVIX | RMEBX | OFVIX / RMEBX | |
| Total Expense Ratio | 0.54 | 1.07 | 50% |
| Annual Report Gross Expense Ratio | 0.54 | 1.07 | 50% |
| Fund Existence | 10 years | 11 years | - |
| Gain YTD | 12.468 | 14.940 | 83% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 10000 | 250 | 4,000% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 269M | 112B | 0% |
| Annual Yield % from dividends | 1.81 | 1.05 | 171% |
| Returns for 1 year | -4.83 | 6.55 | -74% |
| Returns for 3 years | 26.81 | 30.03 | 89% |
| Returns for 5 years | 75.56 | 53.80 | 140% |
| Returns for 10 years | N/A | 92.20 | - |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| RIVJX | 20.78 | 0.19 | +0.92% |
| American Funds International Vntg R-5E | |||
| GAGIX | 36.55 | 0.23 | +0.63% |
| Gabelli Global Rising Income and Div I | |||
| BRSJX | 15.46 | 0.04 | +0.26% |
| MFS Blended Research Small Cap Eq I | |||
| PRWAX | 85.91 | 0.12 | +0.14% |
| T. Rowe Price All-Cap Opportunities Fund | |||
| AVUNX | 21.30 | 0.03 | +0.14% |
| Avantis® U.S. Equity G | |||